Wizemed Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 27.87%
- Ebitda -637.19%
- Net Worth -16.34%
- Total Assets 171.39%
About Wizemed Life Sciences
Wizemed Life Sciences Private Limited (WLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 August 2018 (Six years and five months 8 days old ). Its registered office is in Thiruvananthapuram, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Parvathy Gopan, Ajith Nair, Jeevananthan Sujanya, and One other member serve as directors at the Company.
Company Details
-
Location
Thiruvananthapuram, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KL2018PTC054414
-
Company No.
054414
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Aug 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Wizemed Life Sciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parvathy Gopan
|
Director | 22-Feb-2023 | Current |
|
Ajith Nair
|
Director | 22-Feb-2023 | Current |
|
Jeevananthan Sujanya
|
Director | 28-Aug-2018 | Current |
|
Anitha Krishnaswamy
|
Director | 28-Aug-2018 | Current |
Financial Performance of Wizemed Life Sciences.
Wizemed Life Sciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 27.87% increase in profit. The company's net worth observed a substantial decline by a decrease of 16.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wizemed Life Sciences?
In 2019, Wizemed Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wizemed Life Sciences?
Unlock and access historical data on people associated with Wizemed Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wizemed Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wizemed Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
